Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose M Pacheco

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Cancer Discovery|July 21, 2021
Mobocertinib: A Potential Treatment for NSCLC with EGFR Exon 20 InsertionsJose M Pacheco
Current Opinion in Pulmonary Medicine|January 3, 2020
Approach to stage IV non-small-cell lung cancer: how to select among first-line therapy options?Jose M Pacheco
Journal of Thoracic Disease|November 19, 2020
Immunotherapy for extensive stage small cell lung cancerJose M Pacheco
Journal of Thoracic Disease|November 19, 2020
Systemic therapy options following first-line chemoimmunotherapy in small-cell lung cancerJose M Pacheco
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Antibody drug conjugates in thoracic malignanciesJose M Pacheco, D Ross Camidge
Cancer Discovery|October 3, 2019
Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?Jose M Pacheco, Lauren Averett Byers
Frontiers in Oncology|April 16, 2019
A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung CancerJose M Pacheco, D Ross Camidge, Robert C Doebele, et al.
Breast Cancer Research and Treatment|February 13, 2013
Racial differences in outcomes of triple-negative breast cancerJose M Pacheco, Feng Gao, Caroline Bumb, et al.
Translational Lung Cancer Research|July 23, 2021
Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting systemShuai Bai, Tiantian Tian, Jose M Pacheco, et al.
Breast Cancer Research and Treatment|May 30, 2014
Body mass index, diabetes, and triple-negative breast cancer prognosisSarah Tait, Jose M Pacheco, Feng Gao, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Cancer Discovery|July 21, 2021
Mobocertinib: A Potential Treatment for NSCLC with EGFR Exon 20 InsertionsJose M Pacheco
Current Opinion in Pulmonary Medicine|January 3, 2020
Approach to stage IV non-small-cell lung cancer: how to select among first-line therapy options?Jose M Pacheco
Journal of Thoracic Disease|November 19, 2020
Immunotherapy for extensive stage small cell lung cancerJose M Pacheco
Journal of Thoracic Disease|November 19, 2020
Systemic therapy options following first-line chemoimmunotherapy in small-cell lung cancerJose M Pacheco
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Antibody drug conjugates in thoracic malignanciesJose M Pacheco, D Ross Camidge
Cancer Discovery|October 3, 2019
Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?Jose M Pacheco, Lauren Averett Byers
Frontiers in Oncology|April 16, 2019
A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung CancerJose M Pacheco, D Ross Camidge, Robert C Doebele, et al.
Breast Cancer Research and Treatment|February 13, 2013
Racial differences in outcomes of triple-negative breast cancerJose M Pacheco, Feng Gao, Caroline Bumb, et al.
Translational Lung Cancer Research|July 23, 2021
Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting systemShuai Bai, Tiantian Tian, Jose M Pacheco, et al.
Breast Cancer Research and Treatment|May 30, 2014
Body mass index, diabetes, and triple-negative breast cancer prognosisSarah Tait, Jose M Pacheco, Feng Gao, et al.
Pageof 3